De Novo device
iTind System
Medi-Tate , Ltd. · Temporarily-Placed Urethral Opening System For Symptoms Of Benign Prostatic Hyperplasia (QKA, Class II) · First FDA decision Feb 25, 2020, newest Jun 25, 2021Enlarged prostate (BPH)
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
De Novo pathway
Device trials
8
Naming "iTind"
MAUDE reports
0
Brand "iTind", since 2015
PubMed studies
86
Mentioning "iTind"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing iTind System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 0 of 2 decisions filed under this name.
FDA's records could not be loaded.
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Fluid Jet System in the Treatment of Benign Prostatic Hyperplasia (BPH)Local determinationIn effectL38378CGS Administrators, LLCUpdated Mar 25, 2026
- PSA (Addition of ICD-9-CM 600.21, Benign localized hyperplasia of prostate with urinary obstruction as a covered indication)Coding analysisReview closedCAG-00332NUpdated Sep 15, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "iTind", any status and sponsor, newest update first.
Medi-Tate Ltd.Not on our public-company list
NCT03395522 · 149 participants · Start Feb 18, 2018 · Primary completion Jun 18, 2023
Device: iTind · For: BPH
Sites: Sydney, Australia; Bordeaux, France; Paris, France · 12 sites in all
Chinese University of Hong KongAcademic, hospital or other
NCT05440981 · 13 participants · Start Sep 1, 2022 · Primary completion Jan 15, 2025
Device: iTind device · For: Prostate Hyperplasia
Sites: Shatin, Hong Kong
- Post-Market Study to Assess iTind Safety in Comparison to UroLiftPivotal-lookingRecruiting
Olympus Corporation of the AmericasPublic (7733.T)
NCT04757116 · 256 participants (planned) · Start Sep 26, 2022 · Primary completion Jul 15, 2027
Device: iTind · For: Benign Prostatic Hyperplasia (BPH)
Sites: Phoenix, Arizona; Tucson, Arizona; Fresno, California · 19 sites in all
5 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "iTind", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code QKA
22 reports: 0 malfunction, 22 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "iTind"[tiab]. The summary above synthesizes these.
- Minimally Invasive Treatments for Benign Prostatic Obstruction: A Systematic Review and Network Meta-analysis.
Cornu JN, Zantek P, Burtt G, et al. · Eur Urol · 2023Systematic Review, Research Support, Non-U.S. Gov't
- Office-Based Procedures for BPH.
Gao B, Lu S, Bhojani N, et al. · Curr Urol Rep · 2021Review
- iTIND for BPH: Technique and procedural outcomes: A narrative review of current literature.
Fiori C, De Cillis S, Volpi G, et al. · Turk J Urol · 2021
- Systematic review and network meta-analysis of re-intervention rates of new surgical interventions for benign prostatic hyperplasia.
Shin BNH, Qu L, Rhee H, et al. · BJU Int · 2024Systematic Review, Network Meta-Analysis
- An Evaluation of Sexual Function in the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia in Men Treated with the Temporarily Implanted Nitinol Device.
Elterman D, Alshak MN, Martinez Diaz S, et al. · J Endourol · 2023Randomized Controlled Trial, Multicenter Study
- UroLift, Rezūm, and iTind for Benign Prostatic Hyperplasia.
Cheema AS, Long BG, Moore KE, et al. · Urol Clin North Am · 2025Review
- iTIND: the second-generation temporary implantable nitinol device for minimally invasive treatment of benign prostatic hyperplasia.
Balakrishnan D, Jones P, Somani BK · Ther Adv Urol · 2020Review
- The iTind Temporarily Implanted Nitinol Device for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Multicenter, Randomized, Controlled Trial.
Chughtai B, Elterman D, Shore N, et al. · Urology · 2021Multicenter Study, Randomized Controlled Trial
- Temporary implantable nitinol device for benign prostatic hyperplasia-related lower urinary tract symptoms: over 48-month results.
Amparore D, De Cillis S, Schulman C, et al. · Minerva Urol Nephrol · 2023Multicenter Study
- Reasons for new MIS. Let's be fair: iTIND, Urolift and Rezūm.
Suarez-Ibarrola R, Miernik A, Gratzke C, et al. · World J Urol · 2021Review
- [Minimally Invasive Treatment of Benign Prostate Enlargement].
Rieken M · Ther Umsch · 2023Comparative Study, English Abstract
- Ejaculation sparing of classic and minimally invasive surgical treatments of LUTS/BPH.
Busetto GM, Lombardo R, De Nunzio C, et al. · Prostate Cancer Prostatic Dis · 2025Systematic Review
Other devices of this type
Also filed under product code QKA.
- Urocross Expander System (UES-2018-C1)Prodeon Medical, Inc. · 510(k) 2026
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.